COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review
- PMID: 33555378
- PMCID: PMC7868660
- DOI: 10.1007/s00203-021-02183-z
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review
Abstract
The Covid-19 pandemic is highly contagious and has spread rapidly across the globe. To date there have been no specific treatment options available for this life-threatening disease. During this medical emergency, target-based drug repositioning/repurposing with a continuous monitoring and recording of results is an effective method for the treatment and drug discovery. This review summarizes the recent findings on COVID-19, its genomic organization, molecular evolution through phylogenetic analysis and has recapitulated the drug targets by analyzing the viral molecular machinery as drug targets and repurposing of most frequently used drugs worldwide and their therapeutic applications in COVID-19. Data from solidarity trials have shown that the treatment with Chloroquine, hydroxychloroquine and lopinavir-ritonavir had no effect in reducing the mortality rate and also had adverse side effects. Remdesivir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19. Recent clinical trial has revealed that dexamethasone and convalescent plasma treatment can reduce mortality in patients with severe forms of COVID-19.
Keywords: COVID-19; Dexamethasone; Drug repositioning/repurposing; Favipiravir; Molecular targets; Remdesivir; Ribavarin.
Conflict of interest statement
None of the authors have any conflict of interest to declare.
Figures
Similar articles
-
[The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].Recenti Prog Med. 2021 Mar;112(3):195-206. doi: 10.1701/3565.35458. Recenti Prog Med. 2021. PMID: 33687358 Italian.
-
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13. J Infect Public Health. 2020. PMID: 32684351 Free PMC article.
-
Possible treatment and strategies for COVID-19: review and assessment.Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12593-12608. doi: 10.26355/eurrev_202012_24057. Eur Rev Med Pharmacol Sci. 2020. PMID: 33336780 Review.
-
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.Antimicrob Agents Chemother. 2020 Aug 20;64(9):e01101-20. doi: 10.1128/AAC.01101-20. Print 2020 Aug 20. Antimicrob Agents Chemother. 2020. PMID: 32631826 Free PMC article. Review.
-
Gender differences in treatment of Coronavirus Disease-2019.Monaldi Arch Chest Dis. 2020 Dec 3;90(4). doi: 10.4081/monaldi.2020.1508. Monaldi Arch Chest Dis. 2020. PMID: 33305554
Cited by
-
Immunohistochemical Analysis of Spermatogenesis in Patients with SARS-CoV-2 Invasion in Different Age Groups.Curr Issues Mol Biol. 2023 Mar 16;45(3):2444-2451. doi: 10.3390/cimb45030159. Curr Issues Mol Biol. 2023. PMID: 36975529 Free PMC article.
-
A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants.Arch Microbiol. 2023 Mar 26;205(4):142. doi: 10.1007/s00203-023-03461-8. Arch Microbiol. 2023. PMID: 36966200 Free PMC article. Review.
-
Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia.Biomedicines. 2022 Mar 31;10(4):820. doi: 10.3390/biomedicines10040820. Biomedicines. 2022. PMID: 35453570 Free PMC article.
-
Health-Promoting Properties of Medicinal Mushrooms and Their Bioactive Compounds for the COVID-19 Era-An Appraisal: Do the Pro-Health Claims Measure Up?Molecules. 2022 Apr 1;27(7):2302. doi: 10.3390/molecules27072302. Molecules. 2022. PMID: 35408701 Free PMC article. Review.
-
The impact of COVID-19 on the male reproductive tract and fertility: A systematic review.Arab J Urol. 2021 Aug 9;19(3):423-436. doi: 10.1080/2090598X.2021.1955554. eCollection 2021. Arab J Urol. 2021. PMID: 34552795 Free PMC article. Review.
References
-
- Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9:2. doi: 10.1128/mBio.00221-18. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical